Trials / Completed
CompletedNCT00637702
A Study of ARRY-334543 in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive a new formulation of investigational study drug ARRY-334543. Patients will receive increasing doses of study drug in order to achieve the highest dose possible that will not cause unacceptable side effects. The patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. In addition, the effect of food on the new formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this study (Active, not recruiting).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-334543, EGFR/ErbB2 inhibitor; oral | single dose and multiple dose, escalating |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2008-03-18
- Last updated
- 2020-10-08
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00637702. Inclusion in this directory is not an endorsement.